Drug Profile
Thiotepa - Sumitomo Pharma
Alternative Names: DSP 1958; RETHIO; RITHIO®Latest Information Update: 05 Apr 2022
Price :
$50
*
At a glance
- Originator Sumitomo Dainippon Pharma
- Developer Sumitomo Pharma
- Class Antineoplastics; Aziridines; Myeloablative agonists; Organothiophosphorus compounds
- Mechanism of Action Alkylating agents; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Lymphoma; Solid tumours
- No development reported Haematological disorders